McKesson News

McKesson Corporation to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

Read More

McKesson Declares Quarterly Dividend May 24, 2017

Read More

Biologics’ Patient Access Services Team Procures more than $44 Million in Co-pay Assistance for Cancer Patients in 2016

Read More

IMFINZI (durvalumab) Approved for Previously Treated Patients with Advanced Bladder Cancer, available immediately at Biologics, Inc.

Read More

McKesson Reports Fiscal 2017 Fourth-Quarter and Full-Year Results

Read More

McKesson Specialty Health Selected by TESARO to provide ZEJULA (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

Read More

ALUNBRIG (brigatinib) Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.

Read More

RYDAPT (midostaurin) Approved for the Treatment of FLT3-Mutated Acute Myeloid Leukemia, available for order at Biologics, Inc.

Read More

Thought Leaders from McKesson Specialty Health and The US Oncology Network Are Key Presenters at the 2017 Community Oncology Conference

Read More

US Oncology Research Enrolls 2,900 Patients in Leading-Edge Clinical Trials in Twelve Months

Read More

Biologics, Inc. Selected by TESARO as a Specialty Pharmacy Provider for ZEJULA (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

Read More

McKesson Corporation Fiscal 2017 Fourth Quarter Conference Call Scheduled for May 18, 2017

Read More

McKesson Response to Arkansas Department of Correction’s Planned Executions

Read More

McKesson Presents New Approaches to Patient-Centric Behavioral Coaching at CBI Conference

Read More

McKesson Completes Acquisition of CoverMyMeds

Read More

Faster, Simpler, Smarter: InterQual 2017 Streamlines Clinical Care Decisions

Read More

McKesson ideaShare: Shaping the Independent’s Power to Perform

Read More

BAVENCIO (avelumab) Approved for the Treatment of Metastatic Merkel Cell Carcinoma, Available for Order at Biologics, Inc.

Read More

KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, available for order at Biologics, Inc.

Read More

McKesson and Change Healthcare Complete the Creation of New Healthcare Information Technology Company

Read More

McKesson Provides Financial Update to Reflect Creation of a New Healthcare Information Technology Company

Read More

Medical Oncology Hematology Consultants Joins The US Oncology Network

Read More

XERMELO (telotristat ethyl) Approved for the Treatment of Carcinoid Syndrome, Available for Order Immediately at Biologics, Inc.

Read More

Harrisonburg Emergency Physicians Select McKesson

Read More

Black Book Research Recognizes iKnowMed as the Number One Ranked Oncology Electronic Health Record for Sixth Consecutive Year

Read More

McKesson Reinventing Revenue Cycle Management for a Value-Based World

Read More

Wake County EMS Selects McKesson

Read More

McKesson HealthQx First to be Certified on Latest Version of PROMETHEUS Care Episodes

Read More

Oregon Advanced Imaging Selects McKesson for Revenue Cycle Management

Read More

Value-based Care Services Provider, ACO Partner, Gains Traction in Arizona

Read More